Recent News

BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director

Berkeley, CA and Vancouver, BC – October 26, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, is pleased to announce the appointment of Dr. William Williams, as its President, CEO and […]

News and Events, Recent News

BioNap Consulting’s Jason Napodano Issues an Update on BriaCell Therapeutics Corp.

Berkeley, CA and Vancouver, BC–(Marketwired – September 27, 2016) – BioNap Consulting, Inc.’s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing of BriaVax™, BriaCell’s proprietary allogeneic whole tumor cell vaccine, in late-stage […]

News and Events, Recent News

BRIACELL APPOINTS NEW YORK-BASED RK EQUITY ADVISORS AND TRUENORTH LIFESCIENCES AS CORPORATE ADVISOR

Berkeley, CA and Vancouver, BC – September 15, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the “Agreement”) with RK Equity Advisors LLC and TrueNorth Lifesciences LLC (“RK TrueNorth”) for the provision of corporate advisory services. The Agreement is […]

News and Events, Recent News

BriaCell Closes Oversubscribed Non-Brokered Private Placement

BERKELEY, CALIFORNIA and VANCOUVER, BRITISH COLUMBIA–(Marketwired – Aug. 19, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE:BCT)(OTCQB:BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the “Offering”) of units (the “Units”) for aggregate gross proceeds to the Company in the amount of $1,700,000. Under the Offering, […]

News and Events, Recent News

BriaCell Appoints the Lead Principal Investigator and First Clinical Site for its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer

– Dr. Jarrod P. Holmes, a prominent breast cancer vaccine expert to lead the study out of St. Joseph Health-Sonoma County Berkeley, CA and Vancouver, BC – August 17, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist […]

News and Events, Recent News

BriaCell Announces Non-Brokered Private Placement

BriaCell Therapeutics Corp. (OTCQB:BCTXF)(TSX VENTURE:BCT) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to $1,500,000. Under the Offering, each Unit shall consist of one common […]

Recent News

BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer

BERKELEY, CA and VANCOUVER, BC–(Marketwired – May 18, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to initiate Phase I/IIa clinical studies and regulatory filings for BriaVax™, […]

News and Events, Recent News

BRIACELL ADDS U.S. BIOTECH VETERAN TO ITS BOARD OF DIRECTORS

Berkeley, CA and Vancouver, BC – Tuesday May 10, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced a change to its board of directors. BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to its Board of Directors. Mr. Schmieg, with 35 years of business experience, […]

Recent News

BriaCell Completes Previously Announced Investment with Leading U.S. Biotech Fund and Non-Brokered Private Placement

Berkeley, CA and Vancouver, BC – May 3, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross proceeds of C$1,275,000. BriaCell intends to use the proceeds from the financings […]

News and Events, Recent News

BriaCell Announces Non-Brokered Private Placement

BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to C$600,000. The Offering is in addition to the Company’s proposed strategic […]